This trial is testing a new cancer treatment in children and young adults with DSRCT that has come back or continued after other treatments.
1 Primary · 6 Secondary · Reporting Duration: Baseline to date of CR (Estimated up to 12 Months)
Side Effects for
Awards & Highlights
2 Treatment Groups
Cyclophosphamide + Vinorelbine
1 of 2
Ramucirumab + Cyclophosphamide + Vinorelbine
1 of 2
34 Total Participants · 2 Treatment Groups
Primary Treatment: Ramucirumab · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 12 - 29 · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are the elderly included in this trial?
"According to the guidelines for who can participate in this research, 12 months is the youngest age allowed and 29 years old is the oldest age limit." - Anonymous Online Contributor
Is this clinical trial being conducted at more than one hospital in the state?
"Presently, this study is being conducted in hospitals located in Jacksonville, Fort Myers, Indianapolis and 31 other cities. If you wish to enroll in the trial, try and select a location near to reduce travel time commitments." - Anonymous Online Contributor
To whom does this trial cater?
"Eligible patients for this study must have desmoplastic small round cell tumor and be between 12 months to 29 years old. This trial is looking to enroll 34 individuals in total." - Anonymous Online Contributor
How many people are chosen to participate in this experiment?
"The data on clinicaltrials.gov does indicate that this study is actively recruiting participants. The trial was first posted on 1/22/2020 and last updated on 9/8/2022. A total of 34 participants are needed for the trial, which will be conducted at 34 different locations." - Anonymous Online Contributor
Could you tell me about other research that has been conducted using Ramucirumab?
"Ramucirumab was first studied in 1997 at City of Hope Comprehensive Cancer Center. As of now, 1288 clinical trials have been completed with 955 still active. A majority of these ongoing studies are based in Jacksonville, Florida." - Anonymous Online Contributor
What are the most common conditions that doctors use Ramucirumab to treat?
"Ramucirumab is commonly used as an effective treatment for multiple sclerosis, leukemia, myelocytic, acute, and malignant neoplasms." - Anonymous Online Contributor
Are people currently being signed up for this clinical trial?
"Yes, as of 9/8/2022 this clinical trial is still recruiting participants, according to the information posted on clinicaltrials.gov. This study was originally advertised on 1/22/2020." - Anonymous Online Contributor